Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial
- JAMA Oncol., Published Online: July 7, 2022;8(9):1271-1277. | doi:10.1001/jamaoncol.2022.2310
